Cowen and Company Reiterates “Hold” Rating for Myriad Genetics, Inc. (MYGN)

Myriad Genetics, Inc. (NASDAQ:MYGN)‘s stock had its “hold” rating reiterated by Cowen and Company in a research report issued to clients and investors on Friday. They currently have a $25.00 price target on the stock. Cowen and Company’s price target suggests a potential upside of 1.21% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the company. BidaskClub upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a report on Saturday, June 17th. Jefferies Group LLC restated a “hold” rating and issued a $21.00 price target (up previously from $18.00) on shares of Myriad Genetics in a report on Wednesday, May 3rd. Deutsche Bank AG upped their price target on Myriad Genetics from $15.00 to $20.00 and gave the stock a “sell” rating in a report on Monday, May 8th. Finally, J P Morgan Chase & Co restated an “underweight” rating and issued a $16.00 price target on shares of Myriad Genetics in a report on Friday, June 30th. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $22.00.

Myriad Genetics (NASDAQ MYGN) opened at 24.70 on Friday. The stock has a market cap of $1.68 billion, a P/E ratio of 52.78 and a beta of 0.32. Myriad Genetics has a 52-week low of $15.15 and a 52-week high of $32.54. The stock has a 50 day moving average price of $22.64 and a 200 day moving average price of $19.25.

Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, May 2nd. The company reported $0.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.03. Myriad Genetics had a return on equity of 10.53% and a net margin of 4.26%. The company had revenue of $196.90 million for the quarter, compared to analysts’ expectations of $188.89 million. On average, equities research analysts forecast that Myriad Genetics will post $1.01 EPS for the current year.

WARNING: This piece was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://transcriptdaily.com/2017/07/18/cowen-and-company-reiterates-hold-rating-for-myriad-genetics-inc-mygn.html.

A number of large investors have recently made changes to their positions in MYGN. BlackRock Inc. boosted its stake in shares of Myriad Genetics by 168,335.7% in the first quarter. BlackRock Inc. now owns 9,541,884 shares of the company’s stock worth $183,203,000 after buying an additional 9,536,219 shares during the period. Vanguard Group Inc. raised its position in shares of Myriad Genetics by 16.8% in the first quarter. Vanguard Group Inc. now owns 6,251,030 shares of the company’s stock worth $120,020,000 after buying an additional 897,287 shares in the last quarter. Camber Capital Management LLC raised its position in shares of Myriad Genetics by 6.5% in the first quarter. Camber Capital Management LLC now owns 4,325,000 shares of the company’s stock worth $83,040,000 after buying an additional 265,000 shares in the last quarter. Frontier Capital Management Co. LLC raised its position in shares of Myriad Genetics by 1.4% in the first quarter. Frontier Capital Management Co. LLC now owns 3,075,954 shares of the company’s stock worth $59,058,000 after buying an additional 41,432 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Myriad Genetics by 59.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,642,820 shares of the company’s stock worth $50,742,000 after buying an additional 987,966 shares in the last quarter.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply